ArticleCureus2026
Glioblastoma With a Primitive Neuronal Component: A Case Report and Review of the Literature.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) with a primitive neuronal component (PNC) is an uncommon GBM subtype. We report a rare case of GBM with PNC originating in the left frontal lobe and review the relevant literature. A 60-year-old woman with no previous medical history presented with a generalized seizure. MRI revealed a lesion with ring enhancement in the left frontal lobe, suggestive of a high-grade glioma. The patient underwent gross total tumor resection. Intraoperative pathological examination suggested a high-grade glioma; therefore, photodynamic therapy was applied to the resection cavity. Histopathological examination revealed an isocitrate dehydrogenase-wild-type GBM with PNC. The patient received chemoradiation therapy with temozolomide following the Stupp protocol. However, the tumor recurred rapidly within five months after resection, and bevacizumab was initiated. The tumor decreased in size after bevacizumab administration, and no distant metastasis was confirmed on whole-body CT for at least 25 months. GBM with PNC is a newly recognized and rare GBM subtype characterized by early onset, poor prognosis, and a higher propensity for extracranial metastasis and CSF dissemination compared with conventional GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.